Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 3/2010

01-03-2010 | Original Article

Hepatic Stellate Cell-Specific Gene Silencing Induced by an Artificial MicroRNA for Antifibrosis In Vitro

Authors: Ying Chang, Hua-jun Jiang, Xue-mei Sun, Xiao-kun Cai, Xing-xing He, Pei-yuan Li, Wang-xian Tang, Yu-hu Song, Ju-sheng Lin

Published in: Digestive Diseases and Sciences | Issue 3/2010

Login to get access

Abstract

Background

We previously reported that the anti-transforming growth factor-beta1 (TGF-β1) ribozymes directed by T7 and CMV promoters could reverse the character of activated hepatic stellate cells (HSCs) in vitro and improve fibrotic pathology in vivo. However, nonspecific elimination of the effects of TGF-β1 without selectivity might have unfavorable consequences, such as overwhelming inflammation, tissue necrosis, etc.

Aims

To establish an activated-HSC-specific gene silencing method and validate its feasibility for antifibrosis in vitro.

Methods

An artificial intronic microRNA (miRNA) expression system was established, containing three parts: (1) a 1,074-bp SM-α actin promoter SMP8, which is a kind of RNA polymerase II promoter and has no activity in normal liver-derived cells but is switched on during the activation of HSCs, (2) intron1 modified by inserting an artificial pre-miRNA sequence against TGF-β1, and (3) report gene enhanced green fluorescent proteins (EGFP). The feasibility of this system for artificial microRNA expression was validated through microRNA detection by real-time polymerase chain reaction (PCR). Alteration of biological characteristics of HSCs with the anti-TGF-β1 miRNAs was preliminarily evaluated by measuring the expression levels of TGF-β1 and its downstream molecules, including collagen I, matrix metalloproteinase 2 (MMP2), tissue inhibitor of metalloproteinase 1 (TIMP-1), etc.

Results

The microRNA expression system could successfully produce mature anti-TGF-β1 miRNAs in an activated-HSC-specific manner. The microRNA-induced inhibition rate of TGF-β1 reached 70% and above. Accompanied by TGF-β1 suppression, its downstream targets such as collagen I, MMP2, TIMP-1, etc. were also significantly downregulated in vitro.

Conclusions

Activated-HSC-cell-specific gene silencing could be induced well by the artificial intronic microRNA expression system to realize antifibrosis in vitro.
Literature
1.
Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med. 2006;10:76–99.CrossRefPubMed
2.
Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209–218.PubMed
3.
Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology. 2004;126:529–540.CrossRefPubMed
4.
Bridle KR, Crawford DH, Ramm GA. Identification and characterization of the hepatic stellate cell transferrin receptor. Am J Pathol. 2003;162:1661–1667.PubMed
5.
Iredale JP. Models of liver fibrosis: Exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest. 2007;117:539–548.CrossRefPubMed
6.
Qi Z, Atsuchi N, Ooshima A, Takeshita A, Ueno H. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci USA. 1999;96:2345–2349.CrossRefPubMed
7.
Zardi EM, Dobrina A, Ambrosino G, Margiotta D, Polistina F, Afeltra A. New therapeutic approaches to liver fibrosis: A practicable route? Curr Med Chem. 2008;15:1628–1644.CrossRefPubMed
8.
Song YH, Chen XL, Kong XJ, et al. Ribozymes against TGFbeta1 reverse character of activated hepatic stellate cells in vitro and inhibit liver fibrosis in rats. J Gene Med. 2005;7:965–976.CrossRefPubMed
9.
Xu Y, Pasche B. TGF-beta signaling alterations and susceptibility to colorectal cancer. Hum Mol Genet. 2007;16(1):R14–20.CrossRefPubMed
10.
Schaffert D, Wagner E. Gene therapy progress and prospects: Synthetic polymer-based systems. Gene Ther. 2008;15:1131–1138.CrossRefPubMed
11.
Zhang M, Smith EP, Kuroda H, Banach W, Chernausek SD, Fagin JA. Targeted expression of a protease-resistant IGFBP-4 mutant in smooth muscle of transgenic mice results in IGFBP-4 stabilization and smooth muscle hypotrophy. J Biol Chem. 2002;277:21285–21290.CrossRefPubMed
12.
George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: A potential new therapy for hepatic fibrosis. Proc Natl Acad Sci USA. 1999;96:12719–12724.CrossRefPubMed
13.
Shi R, Chiang VL. Facile means for quantifying microRNA expression by real-time PCR. Biotechniques. 2005;39:519–525.CrossRefPubMed
14.
Zeng Y, Wagner EJ, Cullen BR. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell. 2002;9:1327–1333.CrossRefPubMed
15.
Zeng Y, Cullen BR. Sequence requirements for micro RNA processing and function in human cells. RNA. 2003;9:112–123.CrossRefPubMed
16.
Zhou H, Xia XG, Xu Z. An RNA polymerase II construct synthesizes short-hairpin RNA with a quantitative indicator and mediates highly efficient RNAi. Nucleic Acids Res. 2005;33:e62.CrossRefPubMed
17.
Buck AH, Santoyo-Lopez J, Robertson KA, Kumar DS, Reczko M, Ghazal P. Discrete clusters of virus-encoded micrornas are associated with complementary strands of the genome and the 7.2-kilobase stable intron in murine cytomegalovirus. J Virol. 2007;81:13761–13770.CrossRefPubMed
18.
Castoldi M, Schmidt S, Benes V, et al. A sensitive array for microRNA expression profiling (miChip) based on locked nucleic acids (LNA). RNA. 2006;12:913–920.CrossRefPubMed
19.
Rojkind M, Giambrone MA, Biempica L. Collagen types in normal and cirrhotic liver. Gastroenterology. 1979;76:710–719.PubMed
20.
Rayburn ER, Zhang R. Antisense, RNAi, and gene silencing strategies for therapy: Mission possible or impossible? Drug Discov Today. 2008;13:513–521.CrossRefPubMed
21.
22.
Huang C, Li M, Chen C, Yao Q. Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets. 2008;12:637–645.CrossRefPubMed
23.
Rockey DC. Gene therapy for hepatic fibrosis-bringing treatment into the new millennium. Hepatology. 1999;30:816–818.CrossRefPubMed
24.
Spankuch B, Strebhardt K. RNA interference-based gene silencing in mice: The development of a novel therapeutical strategy. Curr Pharm Des. 2005;11:3405–3419.CrossRefPubMed
25.
Xia XG, Zhou H, Xu Z. Transgenic RNAi: Accelerating and expanding reverse genetics in mammals. Transgenic Res. 2006;15:271–275.CrossRefPubMed
26.
Cai X, Zhou J, Chang Y, Sun X, Li P, Lin J. Targeting gene therapy for hepatocarcinoma cells with the E. coli purine nucleoside phosphorylase suicide gene system directed by a chimeric alpha-fetoprotein promoter. Cancer Lett. 2008;264:71–82.CrossRefPubMed
27.
Wang J, Niu W, Nikiforov Y, et al. Targeted overexpression of IGF-I evokes distinct patterns of organ remodeling in smooth muscle cell tissue beds of transgenic mice. J Clin Invest. 1997;100:1425–1439.CrossRefPubMed
28.
Moreira RK. Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med. 2007;131:1728–1734.PubMed
29.
Vogel S, Piantedosi R, Frank J, et al. An immortalized rat liver stellate cell line (HSC-T6): A new cell model for the study of retinoid metabolism in vitro. J Lipid Res. 2000;41:882–893.PubMed
30.
Kim Y, Ratziu V, Choi SG, et al. Transcriptional activation of transforming growth factor beta1 and its receptors by the Kruppel-like factor Zf9/core promoter-binding protein and Sp1. Potential mechanisms for autocrine fibrogenesis in response to injury. J Biol Chem. 1998;273:33750–33758.CrossRefPubMed
31.
Zhou XM, Lin JS, Shi Y, et al. Establishment of a screening system for selection of siRNA target sites directed against hepatitis B virus surface gene. Acta Biochim Biophys Sin (Shanghai). 2005;37:310–316.CrossRef
32.
Cramer P, Armache KJ, Baumli S, et al. Structure of eukaryotic RNA polymerases. Annu Rev Biophys. 2008;37:337–352.CrossRefPubMed
33.
Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004;23:4051–4060.CrossRefPubMed
34.
Lin SL, Miller JD, Ying SY. Intronic microRNA (miRNA). J Biomed Biotechnol. 2006;2006:26818.PubMed
35.
36.
Krek A, Grun D, Poy MN, et al. Combinatorial microRNA target predictions. Nat Genet. 2005;37:495–500.CrossRefPubMed
37.
Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell. 2003;115:787–798.CrossRefPubMed
38.
Zhang B, Wang Q, Pan X. MicroRNAs and their regulatory roles in animals and plants. J Cell Physiol. 2007;210:279–289.CrossRefPubMed
39.
Jones-Rhoades MW, Bartel DP, Bartel B. MicroRNAS and their regulatory roles in plants. Annu Rev Plant Biol. 2006;57:19–53.CrossRefPubMed
40.
Rhoades MW, Reinhart BJ, Lim LP, Burge CB, Bartel B, Bartel DP. Prediction of plant microRNA targets. Cell. 2002;110:513–520.CrossRefPubMed
41.
42.
43.
Cheng K, Yang N, Mahato RI. TGF-beta1 gene silencing for treating liver fibrosis. Mol Pharm. 2009;6:772–779.CrossRefPubMed
44.
Kim KH, Kim HC, Hwang MY, et al. The antifibrotic effect of TGF-beta1 siRNAs in murine model of liver cirrhosis. Biochem Biophys Res Commun. 2006;343:1072–1078.CrossRefPubMed
45.
Li G, Xie Q, Shi Y, et al. Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats. J Gene Med. 2006;8:889–900.CrossRefPubMed
46.
Xu W, Wang LW, Shi JZ, Gong ZJ. Effects of RNA interference targeting transforming growth factor-beta 1 on immune hepatic fibrosis induced by Concanavalin A in mice. Hepatobiliary Pancreat Dis Int. 2009;8:300–308.PubMed
47.
Schnabl B, Kweon YO, Frederick JP, Wang XF, Rippe RA, Brenner DA. The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology. 2001;34:89–100.CrossRefPubMed
Metadata
Title
Hepatic Stellate Cell-Specific Gene Silencing Induced by an Artificial MicroRNA for Antifibrosis In Vitro
Authors
Ying Chang
Hua-jun Jiang
Xue-mei Sun
Xiao-kun Cai
Xing-xing He
Pei-yuan Li
Wang-xian Tang
Yu-hu Song
Ju-sheng Lin
Publication date
01-03-2010
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 3/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-009-1021-z

Other articles of this Issue 3/2010

Digestive Diseases and Sciences 3/2010 Go to the issue

Original Article

Are the Echogenicities on Intraductal Ultrasonography Really Biliary Microlithiasis?

Correspondence

Impact of a Living Donor Liver Transplant Program for Hepatocellular Carcinoma to the Running Local Deceased Donor Liver Transplant Program

Original Article

Serum Ferritin Is a Clinical Biomarker in Japanese Patients with Nonalcoholic Steatohepatitis (NASH) Independent of HFE Gene Mutation

Original Article

Highly Purified Eicosapentaenoic Acid Ethyl Ester Prevents Development of Steatosis and Hepatic Fibrosis in Rats

Original Article

Long-Term Tegaserod Treatment for Dysmotility-like Functional Dyspepsia: Results of Two Identical 1-year Cohort Studies

Review

Evaluation and Treatment of Iron Deficiency Anemia: A Gastroenterological Perspective
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits